Tumor-derived S100A14 targeted astrocytes via TLR4 to Recruit myeloid-derived suppressor cells promoting brain metastasis and Curdione reversal effect.
[BACKGROUND] Brain metastasis (BrM) is the most common complication with the highest mortality in clinical tumor patients.
APA
Feng Q, Wang XY, et al. (2026). Tumor-derived S100A14 targeted astrocytes via TLR4 to Recruit myeloid-derived suppressor cells promoting brain metastasis and Curdione reversal effect.. Phytomedicine : international journal of phytotherapy and phytopharmacology, 153, 157965. https://doi.org/10.1016/j.phymed.2026.157965
MLA
Feng Q, et al.. "Tumor-derived S100A14 targeted astrocytes via TLR4 to Recruit myeloid-derived suppressor cells promoting brain metastasis and Curdione reversal effect.." Phytomedicine : international journal of phytotherapy and phytopharmacology, vol. 153, 2026, pp. 157965.
PMID
41691987
Abstract
[BACKGROUND] Brain metastasis (BrM) is the most common complication with the highest mortality in clinical tumor patients. The underlying mechanisms of S100A14 in promoting tumor BrM remains unclear, and effective therapeutic compounds targeting S100A14 are currently unavailable.
[PURPOSE] In this study, we aimed to investigate molecular mechanism of tumor-derived S100A14 targeting TLR4, activating astrocytes, and recruiting myeloid-derived suppressor cells (MDSCs) to promote tumor BrM and the underlying mechanisms of curdione in targeting S100A14 to suppress tumor BrM.
[METHODS] S100A14 promoted tumor BrM effects were systematically assessed using intracardiac mice model, TMT-based quantitative proteomics and ELISA assay of clinical patients. Non-contact co-culture systems with primary astrocytes, multiplex cytokine profiling, MDSCs recruitment transwell assay were used to validate the S100A14-astrocyte-MDSCs crosstalk. Cellular Thermal Shift Assay, Drug Affinity Responsive Target Stability (DARTS) assays were adopted to elucidate the therapeutic mechanism of curdione.
[RESULTS] We firstly confirmed that S100A14 was highly expressed in the serum of lung cancer patients with BrM and exhibited a strong negative correlation with breast and lung cancer overall survival. Mechanistically, S100A14 driven tumor BrM by targeting astrocytic Toll-like receptor 4, activating NF-κB signaling, reprogramming astrocytes to secrete pro-inflammatory cytokines (IL-6) and chemokines (CCL2 and CXCL1) to recruit both polymorphonuclear and monocytic MDSCs and eventually establishing brain immunosuppressive niche. Meanwhile, we identified Curdione as a potent, effective S100A14 inhibitor that reversed S100A14-mediated cascade reaction to suppress tumor BrM.
[CONCLUSION] Our findings indicated that S100A14 is a clinically relevant biomarker for early detection and a potential therapeutic target for BrM.
[PURPOSE] In this study, we aimed to investigate molecular mechanism of tumor-derived S100A14 targeting TLR4, activating astrocytes, and recruiting myeloid-derived suppressor cells (MDSCs) to promote tumor BrM and the underlying mechanisms of curdione in targeting S100A14 to suppress tumor BrM.
[METHODS] S100A14 promoted tumor BrM effects were systematically assessed using intracardiac mice model, TMT-based quantitative proteomics and ELISA assay of clinical patients. Non-contact co-culture systems with primary astrocytes, multiplex cytokine profiling, MDSCs recruitment transwell assay were used to validate the S100A14-astrocyte-MDSCs crosstalk. Cellular Thermal Shift Assay, Drug Affinity Responsive Target Stability (DARTS) assays were adopted to elucidate the therapeutic mechanism of curdione.
[RESULTS] We firstly confirmed that S100A14 was highly expressed in the serum of lung cancer patients with BrM and exhibited a strong negative correlation with breast and lung cancer overall survival. Mechanistically, S100A14 driven tumor BrM by targeting astrocytic Toll-like receptor 4, activating NF-κB signaling, reprogramming astrocytes to secrete pro-inflammatory cytokines (IL-6) and chemokines (CCL2 and CXCL1) to recruit both polymorphonuclear and monocytic MDSCs and eventually establishing brain immunosuppressive niche. Meanwhile, we identified Curdione as a potent, effective S100A14 inhibitor that reversed S100A14-mediated cascade reaction to suppress tumor BrM.
[CONCLUSION] Our findings indicated that S100A14 is a clinically relevant biomarker for early detection and a potential therapeutic target for BrM.
MeSH Terms
Animals; Toll-Like Receptor 4; Astrocytes; Myeloid-Derived Suppressor Cells; Brain Neoplasms; Mice; Humans; Female; Male; Cell Line, Tumor; Mice, Inbred C57BL; Mice, Inbred BALB C
같은 제1저자의 인용 많은 논문 (5)
- S100A14 in Tumor-Derived EVs Targets PIAS3 to Reprogram Astrocytes and Induce Immunosuppressive Microenvironment Promoting Brain Metastasis and Germacrone Reversal Effect.
- Initial quantitative analysis of gemstone spectral imaging CT: Analysis and discussion of the application value for the differentiation of small liver metastases (<3 cm).
- Extrahepatic disease clusters and mortality in people with steatotic liver diseases: a prospective analysis of 64,749 females and 113,587 males in the UK Biobank.
- HSSAM-Net: hyper-scale shifted aggregation network for precise colorectal polyp segmentation in endoscopic images.
- Clinical relevance of perioperative changes in circulating tumor cells in resectable colorectal cancer.